Mutation Analysis ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 263 | Cerebrotendinous xanthomatosis | 1 |
263. Cerebrotendinous xanthomatosis
Clinical trials : 6 / Drugs : 11 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04218006 (ClinicalTrials.gov) | December 1, 2019 | 2/1/2020 | A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) | A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) in Families With Kinship Bonds and at Least One Homozygous Patient | Xanthomatosis, Cerebrotendinous | Genetic: Mutation Analysis | TRPHARM | Klinar CRO;Damagen Genetic Diagnostic Center | Enrolling by invitation | N/A | N/A | All | 800 | Turkey |